

May 23, 2024

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai-400051

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

Subject: Investors Presentation Q4-F.Y. 2023-24 – Orchid Pharma Limited (“the Company”)

Dear Sir/Madam,

In continuation to our earlier intimation dated May 17, 2024 regarding the Analyst/Investors Earning Call scheduled to be held on May 24, 2024 at 04:00 P.M. (IST) and in accordance to the requirement of Regulation 30 of SEBI (Listing Obligation and Disclosures Requirement) Regulations, 2015, please find enclosed the Investor Presentation, inter-alia, including the financial performance of the Company w.r.t the quarter ended on March 31, 2024.

The Investor Presentation is also made available on the website of the Company at www.orchidpharma.com

You are requested to take the above on your record.

Thanking You,
For **Orchid Pharma Limited**

Kapil Dayya
Company Secretary & Compliance Officer

Encl.: as above

Orchid Pharma Limited

Financials Q4 & FY 2023-24

• All results in standalone basis.
• These are approx. nos. for exact nos. pls refer financials.

Financial Highlights

QTR-4

FY 23-24



Top line

3%

23%

EBIDTA

1%

37%

PBT

12%

472%

PAT

-50%

72%

Financial Highlights Full Year

Growth Criteria	12M 23-24	9M 23-24	6M 23-24	3M 23-24
Turnover	23.1%	32.1%	28.9%	39.6%
EBIDTA	36.9%	60.9%	43.1%	56.9%
PBT	471.6%	674.8%	278.2%	176.6%
PAT	71.6%	674.8%	278.2%	176.6%


* Comparison YOY

Financial Performance Summary




(Rs/Crore)	Q4-2024	Q4-2023	Change %	12M-31 st Mar'24	12M-31 st Mar'23	Change %
Sales	217.1	209.9	+3%	819.4	665.9	+23%
Other Income	12.9	1.7		30.4	19.4	
COGS	128.1	118.9		484.6	384.6	
Employee Exp	17.6	16.4		69.6	65.4	
Other Exp	42.5	34.9		154.6	132.3	
EBITDA	41.8	41.4	+1%	141.0	103.0	+37%
% to Sales	19%	20%		17%	15%	
Interest	3.4	7.5	-55%	16.3	32.2	-49%
Depreciation	8.4	7.2	+17%	33.2	54.8	-39%
PBT	30.0	26.7		91.5	16.0	
PAT	33.2	65.9		94.7	55.2	

Turnover (In Cr.)




EBITDA, PBT & PAT as % to Sales 12M




P&L Analysis – Gross Margin % to Sales



Gross Margin for Yearly



P&L Analysis – Exp. % to Sales 12M



Thank You